Momenta Pharmaceuticals, Inc. (MNTA)

[indigokid]

Orencia - Sales continue to increase

Not sure if posted here yet...but of interest as guessing this will likely come to market before M-Humira.

3Q16 Orencia Sales at a $2.1b annualized run rate globally and roughly $1.5B in US.

Also, approved for new indications in EU (See below) Not as interesting near term as EU patents appear to run for an additional 5 years (after US expiration) and only account for 25% of the market...

But this is partnered with Mylan globally so should eventually be valuable.

From 3Q10Q...

Orencia - a fusion protein indicated for adult patients with moderate to severe active RA and is also indicated for reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
•
In September 2016, the Company announced the EC approved Orencia intravenous infusion and subcutaneous injection, in combination with methotrexate(MTX), for the treatment of highly active and progressive disease in adult patients with RA not previously treated with MTX. With this approval, Orencia is the first biologic therapy with an indication in the EU specifically applicable to the treatment of MTX-naive RA patients with highly active and progressive disease. This approval allows for the expanded marketing of Orencia in all 28 Member States of the EU.
•
In July 2016, the Company announced the commercial launch of the Orencia ClickJect Autoinjector, a new self-administered autoinjector for adults with moderate to severe RA